1. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Issue 9 (September 2019) Authors: Mateos, Maria-Victoria; Blacklock, Hilary; Schjesvold, Fredrik; Oriol, Albert; Simpson, David; George, Anupkumar; Goldschmidt, Hartmut; Larocca, Alessandra; Chanan-Khan, Asher; Sherbenou, Daniel; Avivi, Irit; Benyamini, Noam; Iida, Shinsuke; Matsumoto, Morio; Suzuki, Kenshi; Ribrag, Vincent; Usma... Journal: Lancet Issue: Volume 6:Issue 9(2019) Page Start: e459 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗